FibroGen (FGEN) Competitors $0.27 -0.04 (-11.83%) As of 01:28 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. GLSI, TARA, HURA, PLX, CABA, THTX, CCCC, CRDL, CRBU, and ATOSShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Greenwich LifeSciences (GLSI), Protara Therapeutics (TARA), TuHURA Biosciences (HURA), Protalix BioTherapeutics (PLX), Cabaletta Bio (CABA), Theratechnologies (THTX), C4 Therapeutics (CCCC), Cardiol Therapeutics (CRDL), Caribou Biosciences (CRBU), and Atossa Therapeutics (ATOS). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Greenwich LifeSciences Protara Therapeutics TuHURA Biosciences Protalix BioTherapeutics Cabaletta Bio Theratechnologies C4 Therapeutics Cardiol Therapeutics Caribou Biosciences Atossa Therapeutics Greenwich LifeSciences (NASDAQ:GLSI) and FibroGen (NASDAQ:FGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Do insiders & institutionals have more ownership in GLSI or FGEN? 4.2% of Greenwich LifeSciences shares are owned by institutional investors. Comparatively, 72.7% of FibroGen shares are owned by institutional investors. 51.7% of Greenwich LifeSciences shares are owned by company insiders. Comparatively, 3.1% of FibroGen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts rate GLSI or FGEN? Greenwich LifeSciences presently has a consensus target price of $39.00, suggesting a potential upside of 316.44%. FibroGen has a consensus target price of $10.00, suggesting a potential upside of 3,576.47%. Given FibroGen's higher possible upside, analysts plainly believe FibroGen is more favorable than Greenwich LifeSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenwich LifeSciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Does the MarketBeat Community believe in GLSI or FGEN? FibroGen received 338 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 58.81% of users gave FibroGen an outperform vote while only 47.37% of users gave Greenwich LifeSciences an outperform vote. CompanyUnderperformOutperformGreenwich LifeSciencesOutperform Votes947.37% Underperform Votes1052.63% FibroGenOutperform Votes34758.81% Underperform Votes24341.19% Which has more risk and volatility, GLSI or FGEN? Greenwich LifeSciences has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, FibroGen has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Which has better earnings and valuation, GLSI or FGEN? Greenwich LifeSciences has higher earnings, but lower revenue than FibroGen. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than FibroGen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreenwich LifeSciencesN/AN/A-$8.89M-$1.26-7.43FibroGen$7.00M3.93-$284.23M-$0.10-2.72 Does the media favor GLSI or FGEN? In the previous week, FibroGen had 2 more articles in the media than Greenwich LifeSciences. MarketBeat recorded 3 mentions for FibroGen and 1 mentions for Greenwich LifeSciences. Greenwich LifeSciences' average media sentiment score of 1.87 beat FibroGen's score of 0.97 indicating that Greenwich LifeSciences is being referred to more favorably in the media. Company Overall Sentiment Greenwich LifeSciences Very Positive FibroGen Positive Is GLSI or FGEN more profitable? Greenwich LifeSciences has a net margin of 0.00% compared to FibroGen's net margin of -67.66%. FibroGen's return on equity of 0.00% beat Greenwich LifeSciences' return on equity.Company Net Margins Return on Equity Return on Assets Greenwich LifeSciencesN/A -185.12% -164.27% FibroGen -67.66%N/A -36.17% SummaryFibroGen beats Greenwich LifeSciences on 10 of the 16 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.48M$6.92B$5.61B$8.57BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-0.228.6327.2219.81Price / Sales3.93265.57411.31154.51Price / CashN/A65.8538.3234.64Price / Book-0.156.587.014.65Net Income-$284.23M$143.75M$3.23B$248.05M7 Day Performance-13.18%1.52%-0.06%-0.15%1 Month Performance-9.12%12.43%8.75%4.50%1 Year Performance-76.55%3.67%32.44%13.76% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.5915 of 5 stars$0.27-11.8%$10.00+3,576.5%-73.4%$27.48M$7.00M-0.22570News CoverageGap DownGLSIGreenwich LifeSciences2.262 of 5 stars$9.45-2.2%$39.00+312.7%-33.8%$126.33MN/A-11.813TARAProtara Therapeutics2.4853 of 5 stars$3.27-2.1%$20.50+526.9%+23.0%$126.16MN/A-1.1630Positive NewsAnalyst RevisionHURATuHURA BiosciencesN/A$2.88+2.5%$12.67+339.8%N/A$125.80MN/A0.00N/AGap UpPLXProtalix BioTherapeutics2.6216 of 5 stars$1.54-2.5%$15.00+874.0%+30.0%$122.60M$59.76M-11.85200CABACabaletta Bio2.8888 of 5 stars$2.37-4.4%$20.33+757.9%-85.2%$120.26MN/A-1.1050News CoverageAnalyst ForecastAnalyst RevisionGap DownTHTXTheratechnologiesN/A$2.60+0.8%N/A+99.2%$119.55M$88.67M-26.00140Positive NewsCCCCC4 Therapeutics2.2162 of 5 stars$1.68-2.9%$12.00+614.3%-67.3%$119.29M$39.78M-0.99150Positive NewsGap DownCRDLCardiol Therapeutics2.236 of 5 stars$1.44+2.1%$8.67+501.9%-51.5%$118.96MN/A-3.6920Gap UpCRBUCaribou Biosciences3.4353 of 5 stars$1.27+0.8%$8.50+569.3%-41.1%$118.12M$9.92M-0.77100Positive NewsAnalyst RevisionATOSAtossa Therapeutics1.4859 of 5 stars$0.91+1.6%$6.17+574.6%-32.6%$118.07MN/A-4.168 Related Companies and Tools Related Companies Greenwich LifeSciences Competitors Protara Therapeutics Competitors TuHURA Biosciences Competitors Protalix BioTherapeutics Competitors Cabaletta Bio Competitors Theratechnologies Competitors C4 Therapeutics Competitors Cardiol Therapeutics Competitors Caribou Biosciences Competitors Atossa Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy FGEN Stock Free FGEN Stock Alerts